Dr. Abbey and Texas Retina Dallas Research Team Recognized for Work on 4FRONT-2 Wet AMD Clinical Trial
4DMT recently recognized Dr. Ashkan Abbey and Texas Retina’s dedicated Dallas clinical research team for their contributions to advancing clinical research in genetic medicine through the 4FRONT-2 clinical trial. The 4FRONT-2 study
read more
National Retina Research Network Invites Dr. Shami to Discuss Current Study Protocols
The U.S.-based, federally funded DRCR Retina Network recently invited Texas Retina’s Michel J. Shami, MD, to provide investigators with updates on three of the network’s current studies: Protocol AF: A randomized trial
read more
Monitoring Age-related Macular Degeneration at Home
As the leading cause of vision loss in older adults, age-related macular degeneration (AMD) is the most common reason patients are referred to Texas Retina. It happens when the central part of
read more
New Clinical Trials Available at Texas Retina
Medical researchers continue to make significant advances in the diagnosis and treatment of many retina conditions, discovering new sight-saving treatments for diseases that once robbed patients of their vision. That is why
read more
Texas Retina First in the US to Randomize a Patient in the i-SIGHT2 Bioelectric Therapy for Dry AMD Clinical Trial
The i-SIGHT2 pivotal clinical trial is evaluating the investigational i-Lumen AMD System for patients with intermediate to advanced dry age-related macular degeneration (AMD), and on July 1, 2026, Texas Retina’s Patrick D.
read more Dr. Abbey Participates in ReachMD CME on Sustained-Delivery TKIs for Wet AMD
Texas Retina’s Ashkan M. Abbey, MD, recently participated in a continuing medical education (CME) program through ReachMD, titled, “Redefining Durability in nAMD: The Science and Strategy of Sustained-Delivery TKIs.” During the program,
read more